Aleniglipron: Molecular Structure
Chemical properties, amino acid sequence, and structural analysis
📌TL;DR
- •Molecular formula: C49H55FN9O6P
- •Molecular weight: 916 Da
- •Half-life: Suitable for once-daily oral dosing (specific value not disclosed)
Amino Acid Sequence
46 amino acids
Formula
C49H55FN9O6P
Molecular Weight
916 Da
Half-Life
Suitable for once-daily oral dosing (specific value not disclosed)
Molecular Structure and Properties#
Aleniglipron (GPCR0803) is a non-peptide small molecule GLP-1 receptor agonist developed by Structure Therapeutics. Unlike peptide-based GLP-1 agonists (semaglutide, tirzepatide, liraglutide), aleniglipron is a synthetic organic molecule that activates the GLP-1 receptor through a distinct binding mechanism.
Detailed molecular structure, chemical formula, molecular weight, and exact structure have not been publicly disclosed.
Small Molecule vs. Peptide GLP-1 Agonists#
| Property | Small Molecule (Aleniglipron) | Peptide (e.g., Semaglutide) |
|---|---|---|
| Molecular type | Synthetic organic molecule | 31-amino acid modified peptide |
| Typical molecular weight | <1000 Da | ~4000 Da |
| Oral bioavailability | Generally good | Poor (<1% for oral semaglutide) |
| Injection required | No | Yes (primary formulation) |
| Manufacturing | Chemical synthesis | Peptide synthesis/recombinant |
| Binding site | Allosteric or unique site | Orthosteric (peptide binding pocket) |
| Stability | Generally heat/acid stable | Requires cold chain, acid-sensitive |
Pharmacological Profile#
Aleniglipron is a once-daily oral GLP-1 receptor agonist. The ACCESS program used starting dose of 5 mg with 4-week titration to maintenance doses of 45, 90, or 120 mg, suggesting standard oral pharmacokinetics with a half-life suitable for daily dosing.
Drug Development Context#
Aleniglipron is part of the emerging oral small molecule GLP-1 agonist class alongside orforglipron (Eli Lilly). These molecules could dramatically expand access to GLP-1-based anti-obesity therapy by removing injection barriers.
Molecular Context#
Aleniglipron belongs to the Metabolic category of research peptides. The molecular properties of Aleniglipron determine its pharmacological behavior, including receptor binding, distribution, metabolism, and elimination. Understanding these properties is fundamental to interpreting clinical data and designing research protocols.
Structural Overview#
Aleniglipron is characterized as: Non-peptide small molecule GLP-1 receptor agonist for once-daily oral administration.
Amino Acid Sequence Details#
The amino acid sequence of Aleniglipron is: Not applicable - small molecule, not a peptide. This sequence determines the peptide's three-dimensional structure, receptor binding properties, and biological activity.
Pharmacokinetic Profile#
Half-Life: Suitable for once-daily oral dosing (specific value not disclosed)
The half-life of a peptide influences dosing frequency, duration of effect, and the clinical utility of the compound. Researchers should consider the half-life when designing experimental protocols.
Related Reading#
Frequently Asked Questions About Aleniglipron
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer